Aldeyra Therandshy;aandshy;peuandshy;tics Revenue and Competitors
Estimated Revenue & Valuation
- Aldeyra Therandshy;aandshy;peuandshy;tics's estimated annual revenue is currently $2.6M per year.
- Aldeyra Therandshy;aandshy;peuandshy;tics's estimated revenue per employee is $155,000
Employee Data
- Aldeyra Therandshy;aandshy;peuandshy;tics has 17 Employees.
- Aldeyra Therandshy;aandshy;peuandshy;tics grew their employee count by -26% last year.
Aldeyra Therandshy;aandshy;peuandshy;tics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Quality Assurance | Reveal Email/Phone |
3 | Senior Director, CMC | Reveal Email/Phone |
4 | Chief Development Officer | Reveal Email/Phone |
5 | Associate Director Clinical Operations | Reveal Email/Phone |
6 | Chief Financial Officer | Reveal Email/Phone |
7 | Operations Manager | Reveal Email/Phone |
Aldeyra Therandshy;aandshy;peuandshy;tics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Aldeyra Therandshy;aandshy;peuandshy;tics?
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.
keywords:N/A
N/A
Total Funding
17
Number of Employees
$2.6M
Revenue (est)
-26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aldeyra Therandshy;aandshy;peuandshy;tics News
MDA levels are elevated in the tears of patients with dry eye disease. Reproxalap (Aldeyra Therapeutics) is a first-in-class novel RASP...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.5M | 17 | -11% | N/A |
#2 | $1.5M | 17 | 0% | N/A |
#3 | $2.1M | 17 | -11% | N/A |
#4 | $1.5M | 17 | -11% | N/A |
#5 | $2.2M | 17 | 21% | N/A |